Background: Altered cardiac autonomic control has often been reported in depressed persons and might play an important role in the increased risk for cardiovascular disease (CVD). A negative association between cardiac autonomic control and depression might become specifically clinically relevant in persons 60 years or older as CVD risk increases with age. Methods: This study included data of 321 persons with a depressive disorder and 115 controls participating in the Netherlands Study of Depression in Older Persons (mean age = 70.3 years, 65.7% female). Respiratory sinus arrhythmia (RSA), heart rate (HR), and preejection period (PEP) were measured and compared between depressed persons and controls. In addition, the role of antidepressants and clinical characteristics (e.g., age of depression onset and comorbid anxiety) was examined. Antidepressant-naïve depressed persons had similar HR and RSA to controls, whereas users of antidepressants showed significantly lower RSA. In addition, tricyclic antidepressant users had higher HR (p < .001, d = 0.768) and shorter PEP (p = .014, d = 0.395) than did controls. Conclusions: Depression was not associated with cardiac autonomic control, but antidepressants were in this sample. All antidepressants were associated with low cardiac parasympathetic control and specifically tricyclic antidepressants with high cardiac sympathetic control.
INTRODUCTION

D
epression is a common mental disorder that affects many people and hampers their daily functioning. In addition, there is high comorbidity between depression and somatic disorders, prominently including cardiovascular disease (CVD) (1, 2) . It has been hypothesized that altered functioning of the autonomic nervous system plays an important role in this comorbidity (3) (4) (5) . Autonomic functioning is often operationalized by measuring the effects of sympathetic and parasympathetic nerve activity on target organs. To study the depression-CVD comorbidity, autonomic effects on the heart are an obvious target.
Cardiac autonomic control (CAC) can be measured noninvasively by the preejection period (PEP; indicating sympathetic control (6)), heart rate (HR; combined sympathetic and parasympathetic control (7)), and HR variability (HRV; mainly parasympathetic control (8) ). A combination of shortened PEP, high HR, and low HRV reflects a shift from cardiac parasympathetic to sympathetic control, and this is known to constitute a risk factor for CVD (9) (10) (11) and cardiovascular precursors such as diabetes and the metabolic syndrome (12, 13) . These expressions of altered CAC are also associated with depression (14) (15) (16) . However, recent research in an adult cohort indicated that the relationship between depression and CAC may be driven by the use of antidepressants rather than by the depression itself: antidepressantnaïve depressed patients did not display altered CAC compared with controls, whereas users of different antidepressants had higher HR, lower HRV, and shorter PEP compared with healthy controls (17) (18) (19) . Several studies support the HRV-lowering effects of antidepressants, although findings are not always consistent in magnitude and direction for all types of antidepressants (14, 20, 21) .
Because the older population is already at high risk for developing CVD and display age-related decreases in cardiac parasympathetic control (22) (23) (24) , examining the relationship between CAC and depression in this group seems to be of clinical interest. Although several studies indeed suggested that altered CAC is commonly seen in depressed older people (25, 26) , other studies found no association between several measures of HRV and depression (27, 28) or depressive symptom profiles (29) , indicating that results are inconsistent. In addition, most studies were limited by small sample sizes, samples that consisted only of persons who already had CVD, and few studies took the use of antidepressant into account. It is therefore still not clear whether altered CAC is associated with depressive disorder in a general older population.
A review that summarized research on depression in older persons suggested that late-life depression is related to specific clinical and (neuro)biological features of depression which are different from features modeled for younger depressive patients (30) . The authors indicated that a distinctive profile is present for late-onset and early-onset depression. For instance, cognitive dysfunction, white matter hyperintensities, and other vascular problems are specifically reported in late-onset depression and less in earlyonset depression (30, 31) . This is in line with the vascular depression hypothesis of Alexopoulos et al. (32) , which suggests that (cerebro)vascular disease may predispose, initiate, or perpetuate symptoms in at least some of the participants with late-life depression. Because cerebrovascular problems are closely linked to more generalized vascular diseases, electrocardiographical changes, and CAC (33) (34) (35) , it is also worthwhile investigating the association between age of depression onset and CAC. To our knowledge, only one study previously examined the effects of age of onset on HRV. Although Vasudev et al. (26) reported lower lowfrequency HRV (generally considered as dominance of sympathetic control) in 42 older depressed patients compared with controls, they found no significant difference in lowfrequency HRV between depressed patients with an early age of onset and those with a late age of onset. Extension of the analyses on age of onset with separate cardiac parasympathetic and sympathetic indices and a larger group of depressed patients would be worthwhile. In addition, the association of CAC with other clinical characteristics of late-life depression such as severity and duration of the disorder has not been firmly studied to date.
In this study, we examined the association between CAC and depressive disorders by comparing HR, respiratory sinus arrhythmia (RSA; a measure of HRV), and PEP between depressed persons and controls 60 years or older, taking antidepressant use and other clinical features such as severity, comorbid anxiety, and age of onset into account.
METHODS
Participants
Participants in the present study were derived from the Netherlands Study of Depression in Older persons (NESDO). NESDO is a prospective cohort study conducted among 510 older participants (age ≥ 60 years) designed to examine (predictors of ) the longterm course and consequences of depression in older persons. The rationale, methods, and recruitment strategy have been described in detail elsewhere (36) , but are briefly summarized here. The NESDO cohort included 378 depressed (major depressive disorder [MDD] , dysthymia, or minor depression according to DSM-IV criteria) (37) and 132 nondepressed adults aged 60 through 93 years. Recruitment of depressed older adults took place in five regions in the Netherlands from both mental health care institutes and general practitioners. Persons with a primary diagnosis of dementia, a Mini Mental State Examination score lower than 18 (of 30 points), and insufficient command of the Dutch language were excluded. Nondepressed control persons were recruited from general practitioners. Inclusion criteria for controls were as follows: no lifetime diagnosis of depression, dementia, or other serious psychiatric disorders and good command of the Dutch language. All interviews were audio-taped to monitor the quality of the data. Data collection of the first measurement started in 2007 and was finished in September 2010. The study protocol was approved by the ethical review board of the VU University Medical Center and, subsequently, by the local review boards of each participating center. After providing information about the study, written informed consent from each participant was obtained.
Measurements
Baseline assessment included a complete Composite International Diagnostic Interview (CIDI 2.1 lifetime version), together with other interviews and questionnaires. The CIDI determined the presence of MDD, minor depression, and dysthymia diagnoses in the past 12 months. The CIDI establishes diagnoses according to the DSM-IV criteria (37) and has shown high interrater and testretest reliability and high validity for depressive disorders (38) .
We distinguished two groups: healthy controls without a history of depressive or anxiety disorders not using antidepressant medication and depressed participants with dysthymia or MDD diagnosis in the past 6 months. After exclusion of 60 participants with missing physiological data due to equipment failure during assessment or poor data quality, 13 participants with a minor depression only, and exclusion of 1 control participant with an anxiety diagnosis, the depressed group consisted of 321 participants and the control group of 115 participants.
Physiological Measurement
Physiological measurement was performed with the "Vrije Universiteit Ambulatory Monitoring System" recording the electrocardiogram (ECG) and changes in thorax impedance (dZ) from six electrodes placed on the chest and back of the participants (39, 40) . NESDO participants wore the Vrije Universiteit Ambulatory Monitoring System device during a large part of the NESDO baseline assessment, while participating in different assessment parts (medical examination, interview, and cognitive tasks). The start of the various assessment parts was marked with an event marker to divide the total recording into fixed periods (e.g. The interbeat interval (IBI) time series was extracted from the ECG signal to obtain HR, an indicator of combined cardiac sympathetic and parasympathetic control. We used noninvasive thoracic impedance cardiography to derive the PEP as the time interval between the onset of ventricular depolarization and the opening of the semilunar valves (41), as was done before (40) . Changes in PEP are a reliable index of changes in β-adrenergic inotropic drive to the left ventricle as shown in laboratory studies manipulating β-adrenergic tone by epinephrine infusion (6, 42) , amyl nitrite inhalation (43) , or adrenoceptor blockade (6, 44) . Throughout the text, we therefore refer to PEP as a measure of cardiac sympathetic control, rather than cardiac sympathetic activity because the sympathetic effects on the left ventricle are determined not just by changes in cardiac norepinephrine release but also by adrenoceptor status and circulating catecholamines. In contrast to cardiac norepinephrine spillover (45) or direct recording of the activity of sympathetic nerves (45, 46) , PEP is a measure that can be obtained in large samples of patients and controls.
Both time and frequency domain measures of HRV are used in research on autonomic control and depression. Previous research from our group (and repeated by others) has indicated that the correlations between high-frequency HRV (frequency domain) and RSA (time domain) are very high (approximately 0.9) (47), and that the measures can be used interchangeably. A clear advantage of the peak-valley method on ECG and impedance cardiogram signals over Fourier decomposition of the ECG is that it additionally generates the respiration rate (RR; which was used as a covariate). RSA is a reliable index of cardiac parasympathetic control as shown by experimental research indicating that RSA is generally not altered by sympathectomy (48) and β-adrenergic blockade (49), but is attenuated by 99% after vagal blockade with atropine (8) or scopoloamine methyl nitrate (50) . RSA was obtained by combining the IBI time series with the filtered (0.1-0.4 Hz) dZ signal, which corresponds to the respiration signal. RSA was obtained by subtracting the shortest IBI during HR acceleration in the inspirational phase from the longest IBI during deceleration in the expirational phase for all breaths, as described in detail elsewhere (39) .
Although automated scoring of IBI, RSA, and PEP removes most artifacts and noise, the signals were checked by visual inspection to make sure no arrhythmias-which might be more frequently present in older and depressed adults (51,52)-were included. Preliminary mixed-model analyses showed that differences in HR, RSA, PEP, and RR between depressed persons and controls were similar across all separate assessment conditions (overall test statistics were as follows: 
Clinical Characteristics
Several potentially relevant clinical characteristics were determined. Frequent use (daily or >50% of the time) of antidepressant medication was assessed by copying the names of medicines from the containers brought in by the participants. Medication was classified using the World Health Organization Anatomical Therapeutic Chemical (ATC) classification (53) . We distinguished selective serotonin reuptake inhibitors (SSRIs, ATC code N06AB), tricyclic antidepressants (TCAs, ATC code N06AA), and other antidepressants (including monoamine oxidase inhibitors, nonselective N06AF, and antidepressants classified as N06AX). A derived daily dose (DDD) was calculated for all antidepressants by dividing the participant's mean daily dose used by the defined daily dose recommended by the World Health Organization (53) . In addition, the duration of antidepressant use was determined and expressed in months of use.
The severity of depression was measured among all participants using the 30-item Inventory of Depressive Symptoms (IDS) selfreport version (54) .
To account for antidepressant use and severity of depression, we first distinguished depressed participants using and not using different types of antidepressants. Second, we wanted to further divide the depressed participants not using an antidepressant based on severity. Because the users of antidepressants might have been more severely depressed before starting antidepressant use, and their severity might have significantly decreased since then, severity of depression might be a major confounding factor when comparing antidepressant-naïve and antidepressant-using depressed participants. To advance this issue, we used information from meta-analyses and reviews summarizing clinical trials and longitudinal observational studies on the effects of antidepressants on depressive symptoms scores. On average, antidepressants achieve a reduction in symptom score of 45% (55) (56) (57) (58) (59) . Based on this average reduction, an IDS score for the antidepressant users was calculated that was more likely to represent their severity before they started using this antidepressant (by dividing their current IDS score by 0.55). We subsequently allocated the antidepressantnaïve depressed participants to two groups based on their IDS score. The cutoff point was chosen such that the most severe group matched the mean IDS score of the depressed participants before they started the use of an antidepressant. In this way, a group variable with six categories was constructed: the control group, a depressed group not taking antidepressants with an IDS < 32 (n = 51), a depressed group not taking antidepressants with an IDS ≥ 32 (n = 37), a depressed group taking TCAs (n = 73), a depressed group taking SSRIs (n = 77), and a depressed group taking other antidepressants (n = 83).
The CIDI provided the age of depression onset, which was defined as the first age at which significant depressive symptoms were experienced. A categorical variable was computed based on tertiles: an early age-of-onset group (onset at age ≤40 years), an intermediate age-of-onset group (onset at age >40 and <60 years), and a late age-of-onset group (age of onset at >60 years). The presence of comorbid anxiety was determined using the CIDI and confirmed when a 6-month diagnosis of panic disorder, social phobia, agoraphobia, or generalized anxiety disorder was present in addition to the depressive disorder. The number of depressive episodes experienced was questioned in the CIDI. This count measure was dichotomized in single or recurrent episodes.
Covariates
Several studies have suggested that research investigating RSA should take RR into account as a confounder (39, 60) . We therefore adjusted all RSA analyses for RR. Sociodemographic characteristics included age, sex, and education in years. In addition, various health indicators were included as covariates: body mass index (BMI) was determined as measured weight in kilograms divided by the square of the measured height in meters and included as a continuous variable. Physical activity was measured using the International Physical Activity Questionnaire (61) and expressed in MET-minutes per week (the multiple of the resting metabolic rate of an activity times the minutes this activity was performed). Smoking status was defined as nonsmoker, former smoker, and current smoker. Alcohol use was determined as number of alcohol consumptions a day. Self-reports were used to ascertain the presence of heart disease (including coronary disease, cardiac arrhythmia, angina pectoris, heart failure, and myocardial infarction) and 
Statistical Analyses
Data were analyzed using SPSS 21.0. Characteristics of the depression and control groups were compared using t tests and χ 2 tests. Analyses of variance (ANOVAs) were used to compare HR, RSA, and PEP between the depression group and controls. These analyses were repeated with consideration of covariates. Effect sizes were calculated with Cohen d (1988) defined as the difference in the means between two groups, divided by the pooled SD of these groups.
We subsequently compared the antidepressant and severity groups with the controls on cardiac autonomic measures in unadjusted and fully adjusted ANOVAs. These analyses were repeated within the rest and other separate assessment conditions of the interview. Furthermore, the impact of different clinical characteristics was evaluated. CAC was compared between depressed persons with and without comorbid anxiety disorders; between depressed participants with an early, intermediate, and late age of onset; and between depressed participants with single or recurrent episodes using fully adjusted ANOVAs. Analyses were repeated separately for the antidepressant-naïve depressed participants.
Finally, we performed partial correlation between CAC and the duration of TCA, SSRI, and other antidepressant use and the DDD of these antidepressants. Correlations were adjusted for age and sex (RSA additionally for RR).
Sensitivity analyses were performed excluding alternately CVD patients and depressed participants without a diagnosis in the month before the baseline assessment.
RESULTS
The mean (SD) age of the study sample (n = 436) was 70.3 (7.3) years, 65.7% was female, and 65.2% had less than 12 years of education. Table 1 shows the demographic, life-style, and health characteristics for healthy controls and depressed participants. Compared with the nondepressed persons, depressed persons had less education, a slightly lower BMI, performed less physical activity, were more likely to smoke but less likely to drink, had more chronic diseases, and more often had CVD. Table 2 presents unadjusted and adjusted results of the mean HR, RSA, and PEP for the controls and depressed persons. The depressed group had a borderline higher HR than did the control group (in the fully adjusted analysis 2.5 beats/min higher, p = .07) and no significantly different PEP (in the fully adjusted analysis, p = .45). The depression groups did significantly differ from the control group in mean RSA (in adjusted analysis 4.9 milliseconds lower RSA, p = .001). The effect sizes for lower RSA and higher b Additionally adjusted for body mass index, physical activity, smoking, alcohol use, cardiovascular disease, chronic disease, use of β-blockers, and use of other heart medication (error df = 423 and for RSA error df = 422). HR in the depression group compared with the controls were moderate: d = 0.373 and d = 0.212, respectively. Covariates that associated strongest with HR were education, physical activity, CVD, and the use of β-blocking agents.
Covariates that associated strongest with RSA were RR and β-blocking agents. Covariates that associated strongest with PEP were BMI, β-blocking agents, alcohol use, and CVD. Table 3 describes all characteristics for the groups divided according to antidepressant use and severity. Compared with the depressed persons not taking antidepressants, antidepressant users had less education, performed less physical activity, had fewer chronic diseases, and more often had a comorbid anxiety disorder (mainly social phobia). Figure 1 represents the unadjusted results of ANOVAs on these six groups and HR, RSA, and PEP. The overall group effect for HR was F = 10.86, p < .001. Post hoc Dunnett test revealed that only the depressive TCA users differed significantly in HR from the controls (p < .001). Repetition of these analyses comparing the antidepressant groups with the depressed participants with an IDS ≥ 32 also showed a difference between TCA users and these depressed participants (p < .001). The overall effect for RSA was F = 7.80, p < .001. Post hoc Dunnett test indicated that the depressive TCA (p < .001) and other antidepressant (p = .017) users differed significantly in RSA from the controls. SSRI users have borderline lower RSA (p = .101). The TCA users also had a significantly lower RSA than the depressed participants with IDS ≥ 32 (p < .001). The overall test for the PEP was also significant (F = 3.31, p = .006). Post hoc Dunnett test revealed that the depressive SSRI users have borderline longer PEP (p = .078) compared with the controls. The depressed participants with an IDS ≥ 32 had a significantly longer PEP compared with the TCA users (p = .002). Table 4 presents the results of the fully adjusted analysis of covariance comparing CAC between these groups. The differences in RSA between controls and depressed participants seen in Table 2 seemed to be entirely driven by the use of antidepressants. Depressed participants not using antidepressants had comparable RSA values with those of controls. Depression severity was not associated with CAC. In contrast, however, RSA differed significantly between controls and depressed participants on TCAs (p < .001, effect size d = 0.768), SSRIs (p = .031, effect size d = 0.333), and other antidepressants (p = .013, effect size d = 0.376). The subdivision based on medication use additionally revealed an association between TCA use and higher HR (p < .001, effect size d = 0.921) and shorter PEP (p = .014, effect size d = 0.395). Supplemental Digital Content 1 (http://links.lww.com/PSYMED/A195) shows the results of these analyses for rest conditions only. Findings are very similar, and significant associations are even more pronounced. Highly comparable results were also obtained from analyses within all other separate assessment conditions.
Additional analyses were performed to investigate the role of clinical depressive characteristics. Within the depressed persons, the association of age of onset, comorbid anxiety, and number of experienced depressive episodes with CAC was investigated (graphs can be found in Supplement Digital Content 2, http://links.lww.com/PSYMED/A196). Comparison of HR, RSA, and PEP between depressed persons with early, middle, or late age of onset revealed no differences (p = .78, p = .74, and p = .62, respectively). In addition, HR, RSA, and PEP were similar for depressed persons with and without comorbid anxiety (p = .59, p = .46, and p = .90, respectively). Finally, the comparison of single episode versus multiple episodes also revealed no differences in HR, RSA, or PEP (p = .35, p = .58, and p = .59, respectively). The analyses with antidepressant-naïve participants only yielded similar findings. Table 5 shows the partial correlations between CAC and the duration and DDD of antidepressant use. Correlations were adjusted for age and sex. The duration and DDD of TCA use correlated negatively with RSA and PEP, indicating that a longer duration of use and a higher DDD associated with lower values of RSA and shorter PEP. Although the other correlations correspond with the findings presented in Table 4 in terms of direction, they do not exceed borderline significance.
Sensitivity analyses showed that the exclusion of CVD patients did not alter any of the findings. In addition, excluding all depressed participants who were not depressed in the month before the baseline interview from the analyses also resulted in similar findings.
DISCUSSION
This study among older people showed that-when compared with healthy controls-depressed persons have significantly lower HRV in the respiratory frequency range. This is considered to reflect lower cardiac parasympathetic control (62, 63) . Comparing the users of different antidepressants and antidepressant-naïve depressed persons with healthy controls revealed that depressed persons not using antidepressants do not have altered RSA, HR, or PEP compared with healthy controls, irrespective of their severity scores. In contrast, depressed persons using TCAs had decreased RSA, increased HR, and shortened PEP (medium to large effect sizes). The use of SSRIs and other antidepressants was also associated with decreased RSA with moderate effect sizes. Our findings are in agreement with a previous meta-analysis on much smaller-scale studies in adults (16) and also with smaller-scale studies in older persons (25, (64) (65) (66) that also reported altered autonomic control in depressed older persons. However, these previous studies did not consider the effects of antidepressants, whereas we did.
We see many similarities when we compare the results of the present study among older people with the results we previously obtained in a young to middle-aged adult cohort (17, 18) . In the latter study, the presence of a depressive disorder itself was also not associated with altered CAC but the use of different antidepressants was. However, in these younger adults, we found lower HR and longer PEP in SSRI users but an association between the use of other antidepressants and shorter PEP and high HR (19) , which is not in line with the present findings in an older population. Although proportionally fewer SSRI users and users of antidepressant other than TCAs were present in this older population compared with the adult cohort, the groups were large enough to detect significant associations. An explanation might be that HR is already higher and PEP shorter in older persons and that the more subtle effects of SSRIs and other antidepressants on cardiac sympathetic control are more difficult to detect. Among other studies on CAC and depression in younger adults, there were some studies that did address antidepressant medication and that reported an association between CAC and depressive disorders (14, 16) . It was suggested in previous discussions that differences in results might be due to the inclusion of CVD patients in our sample (20, 67) . Although there is a considerable percentage of CVD patients in our older sample (on average, 17.5%), no significant difference in percentage of CVD patients between depressed participants not using antidepressants and those who use antidepressants was found. In addition, the results of analyses adjusted for the presence of CVD were similar to the results of unadjusted analyses. Moreover, sensitivity analyses excluding all CVD patients also produced similar results.
According to the vascular depression hypothesis, depression may be caused by cerebrovascular problems and these could be reflected in altered peripheral autonomic regulation. The latter chain of events is not supported by our study. Although we do not rule out that part of the depression in these older participants was caused by cerebrovascular problems, these were not reflected in altered CAC. In addition, none of the clinical characteristics of depression taken into account in the present study were significantly associated with any of the autonomic measures. This argues against the idea that altered CAC could have been limited to a specific subgroup of (antidepressant-naïve) depressed older persons.
The strengths of our study are the large sample of control and depressed older persons, both medicated and nonmedicated. In addition, multiple cardiac autonomic measures were available, providing us with reliable indices of parasympathetic and sympathetic control. Finally, the inclusion of different clinical characteristics such as depression severity and age of onset distinguishes our study from previous ones. Some limitations also have to be acknowledged. The crosssectional design makes it impossible to directly attribute the results to the effects of antidepressants. However, extensive analyses of several clinical characteristics make it less likely that the actual cause of our findings lies in differences between antidepressant users and nonusers in these variables. In addition, the finding that a longer duration of TCA use DDD = derived daily dose; RSA = respiratory sinus arrhythmia; PEP = preejection period; M = mean; SD = standard deviation; TCA = tricyclic antidepressant; SSRI = selective serotonin reuptake inhibitor. a DDD is expressed as the daily dose used by the participants divided by the defined daily dose assigned by the World Health Organization. The defined daily dose is the assumed average maintenance dose per day for a drug used for its main indication in adults. Analyses for specific psychoactive medications were performed when at least 20 participants were using that particular medication. b Adjusted for sex and age.
c Additionally adjusted for respiration rate.
and a higher DDD of TCA associates with decreased cardiac parasympathetic control and increased sympathetic control supports the hypothesis that the found effects can actually be attributed to TCA use. Moreover, the longitudinal results of our adult cohort do imply that the associations found have a causal basis (18, 19) . In addition, we cannot completely exclude the possibility that depressed persons using antidepressants differed in one or more aspects (different from the ones we tested) from the depressed participants not using antidepressants. However, the most likely characteristics including differences in depression symptom severity, age of depression onset, recency of the diagnosis, and number of episodes did not seem to explain the findings. In sum, our findings demonstrate that depressed older persons not using antidepressants do not show altered CAC compared with controls, whereas depressed older persons using antidepressants do. It has been widely established that a shift from cardiac parasympathetic to sympathetic control is a risk factor for cardiovascular morbidity and mortality (9) (10) (11) 68) . In previous work among younger adults, we showed that such a shift also predicts future development of the metabolic syndrome and metabolic dysregulations (13, 69) . In addition, we found that the use of antidepressants was also associated with increased blood pressure and hypertension, partially mediated by altered CAC (13, 70) . These previous results suggest that the present findings among older people could be of significant clinical importance and deserve attention and evaluation in clinical practice. The question whether the observed reduction in cardiac parasympathetic control in users of antidepressants actually increases the risk for CVD remains to be answered. The detrimental effects of antidepressants on CAC need to be weighed against their beneficial effects on depression, which themselves could reduce the risk for future heart disease. An article by Rahman et al. (71) suggests that the balance is in favor of antidepressants. They noted a contribution of both major depression and antidepressant use to CVD risk, but the antidepressantnaïve depressive persons had the highest risk. Unfortunately, the aggregated result of the research investigating the risk for CVD by antidepressant use yields no consistent answers, with some studies finding a protective effect, others finding an increased risk, and some finding no relationship (72) (73) (74) (75) (76) (77) . Type of antidepressant, type of cardiac event, and sample characteristics may explain some of the inconsistencies.
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